Switch to:

Beam Therapeutics EBIT

: $-93.39 Mil (TTM As of Mar. 2020)
View and export this data going back to 2020. Start your Free Trial

Beam Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2020 was $-28.36 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2020 was $-93.39 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beam Therapeutics's annualized ROC % for the quarter that ended in Mar. 2020 was -142.09%. Beam Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2020 was -251.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Beam Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2020 was -14.03%.


Beam Therapeutics EBIT Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Beam Therapeutics Annual Data
Dec17 Dec18 Dec19
EBIT 0.00 -116.74 -78.14

Beam Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
EBIT Premium Member Only Premium Member Only -13.11 -17.65 -19.65 -27.73 -28.36

Beam Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2020 was -17.651 (Jun. 2019 ) + -19.649 (Sep. 2019 ) + -27.731 (Dec. 2019 ) + -28.355 (Mar. 2020 ) = $-93.39 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Beam Therapeutics  (NAS:BEAM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beam Therapeutics's annualized ROC % for the quarter that ended in Mar. 2020 is calculated as:

ROC % (Q: Mar. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2019 ) + Invested Capital (Q: Mar. 2020 ))/ count )
=-113.42 * ( 1 - 0% )/( (78.526 + 81.116)/ 2 )
=-113.42/79.821
=-142.09 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Beam Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2020 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2019  Q: Mar. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-113.42/( ( (43.247 + max(-20.802, 0)) + (46.928 + max(-18.889, 0)) )/ 2 )
=-113.42/( ( 43.247 + 46.928 )/ 2 )
=-113.42/45.0875
=-251.56 %

where Working Capital is:

Working Capital(Q: Dec. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.696) - (12.167 + 0 + 11.331)
=-20.802

Working Capital(Q: Mar. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.192) - (13.328 + 0 + 11.753)
=-18.889

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Beam Therapeutics's Earnings Yield (Joel Greenblatt) %for the quarter that ended in Mar. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2020 )
=-93.386/665.7022
=-14.03 %

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Beam Therapeutics EBIT Related Terms


Beam Therapeutics EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)